×
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes
Seelig E., Howlett J., Porter L., Truman L., Heywood J., Kennet J., Arbon EL., Anselmiova K., Walker NM., Atkar R., Pekalski ML., Rytina E., Evans M., Wicker LS., Todd JA., Mander AP., Bond S., Waldron-Lynch F.
DOI
10.1172/jci.insight.99306
Type
Journal
JCI Insight
Publisher
American Society for Clinical Investigation
Publication Date
04/10/2018
Volume
3